Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema-Reference-Cited by-同舟云学术

Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema

Published:2022-10-17 Issue:20 Volume:65 Page:13629-13644
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Davie Rebecca L.¹^ORCID,Edwards Hannah J.¹,Evans D. Michael¹,Hodgson Simon T.¹,Stocks Michael J.²^ORCID,Smith Alun J.³,Rushbrooke Louise J.¹,Pethen Stephen J.¹,Roe Michael B.¹^ORCID,Clark David E.⁴^ORCID,McEwan Paul A.⁵,Hampton Sally L.¹

Affiliation:

1. KalVista Pharmaceuticals Limited, Porton Science Park, Salisbury, SP4 0BF, U.K.

2. School of Pharmacy, University of Nottingham, University Park Campus, Nottingham NG7 2RD, U.K.

3. Sygnature Discovery, Biocity, Pennyfoot Street, Nottingham, NG1 1GR, U.K.

4. Charles River Early Discovery, 6-9 Spire Green Centre, Harlow, Essex CM19 5TR, U.K.

5. Evotec, 114 Innovation Drive Milton Science Park, Abingdon, OX14 4RZ, U.K.

Funder

KalVista Pharmaceuticals

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00921

Reference40 articles.

1. Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema

2. Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy

3. HAE Pathophysiology and Underlying Mechanisms

4. Hereditary angioedema: Epidemiology and burden of disease

5. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma;Neuroglia;2024-07-02

2. Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration;Cell Biochemistry and Biophysics;2024-06

3. Design and synthesis of novel factor XIa Inhibitors with bicyclic isoquinoline and naphthalene fragments;Medicinal Chemistry Research;2024-05-30

4. Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema;Drugs and Drug Candidates;2024-04-07

5. The future of therapeutic options for hereditary angioedema;Annals of Allergy, Asthma & Immunology;2024-04